



**6<sup>th</sup> International Workshop on  
Waldenström's Macroglobulinemia  
October 6-10, 2010  
Venice, Italy**

**Saturday, October 9, 2010**

**Molino Stucky Hilton**

7:00-8:00 AM

Breakfast

Registration

Molino Restaurant

Venetian Foyer (7:00-17:30)

**7:00 AM**

**Consensus Discussions on Treatment Options and Response  
Criteria in WM-Part II**

Drs. Owen (UK) and Treon (USA)

Presentation of Current Consensus Response Criteria and Proposed Updates  
Dr. Owen (UK)

**Session XII Young Investigator Presentations**

**Section I:**

Session Chair: Dr. Ansell (USA)

- |         |                        |   |
|---------|------------------------|---|
| 8:00 AM | Dr. Novak (USA)        | Development of WM cell lines.   |
| 8:15 AM | M. Lewicki (CANADA)    | Assessment of cytokines and chemokines in patients with WM.                   |
| 8:30 AM | Dr. Koulieris (GREECE) | Quantification of IgM kappa and IgM lambda in WM.                             |
| 8:45 AM | S. Guidez (FRANCE)     | SM-IgC as response criteria in WM.  |
| 9:00 AM | Dr. Greco (ITALY)      | Factors predicting malignant evolution of IgM-MGUS and IgM related disorders. |

**Section II:**

Session Chair: Dr. Ocio (SPAIN)

- |          |                     |  |
|----------|---------------------|--|
| 9:15 AM  | Dr. Trojani (ITALY) | Gene expression of malignant and micro-environment cells from WM patients. |
| 9:30 AM  | Dr. Fulciniti (USA) | Sp1 trans-activation in WM.  |
| 9:45 AM  | Dr. Liu (USA)       | Metalloprotease inhibitors and CD27 in WM.                                 |
| 10:00 AM | A. Sacco (USA)      | NVP-BEZ235 exerts anti-tumor activity in WM.                               |

**Section III:**

Session Chair: Dr. Kimby (SWEDEN)

- |          |                       |  |
|----------|-----------------------|--|
| 10:15 AM | Dr. Maltezas (GREECE) | Clinical impact of sFLCs or FLCR on WM.  |
| 10:30 AM | L. Compain (FRANCE)   | Rituximab, Fludarabine and Cyclophosphamide in WM.                             |
| 10:45 AM | Dr. Chitta (USA)      | Induced resistance to Bortezomib and its association with BCL-2 up-regulation. |

